Holen Sie sich die Stockscreener-App
2.16
6.93%
0.14
Vorhandelsmarkt:
2.20
0.04
+1.85%
Schlusskurs vom Vortag:
$2.02
Offen:
$2.33
24-Stunden-Volumen:
26.08M
Relative Volume:
59.27
Marktkapitalisierung:
$8.53M
Einnahmen:
$20,000
Nettoeinkommen (Verlust:
$-10.84M
KGV:
-0.7754
EPS:
-2.7857
Netto-Cashflow:
$-10.07M
1W Leistung:
+11.92%
1M Leistung:
+9.09%
6M Leistung:
-20.88%
1J Leistung:
-16.92%
1-Tages-Spanne:
$2.15
$2.58
1-Wochen-Bereich:
$1.84
$2.58
52-Wochen-Spanne:
$1.7645
$4.18
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Firmenname
Kiora Pharmaceuticals Inc
Sektor
Branche
Telefon
858-224-9600
Adresse
169 SAXONY RD., ENCINITAS
Compare KPRX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.16 | 8.53M | 20,000 | -10.84M | -10.07M | -2.7857 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.19B | 606.42M | -1.28B | -997.58M | -6.403 |
Kiora Pharmaceuticals Inc Aktie (KPRX) Neueste Nachrichten
KPRX Faces Tumultuous Trading: Strategic Moves Amid Market Fluctuations - timothysykes.com
KiORa Pharmaceuticals (KPRX) Stock: Jumps 24% After $24M Private Placement Deal - parameter.io
Kiora Pharmaceuticals closes $24M private placement By Investing.com - Investing.com South Africa
Kiora Pharmaceuticals’ Stock Analysis amidst Financial Challenges - StocksToTrade
Kiora Pharmaceuticals Inc. Poised for Strategic Expansion Amid Market Challenges - timothysykes.com
According to the latest filings disclosed by the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Kiora Pharmaceuticals (stock code: KPRX) plans to privately place 438,471 shares of its common stock to specific investors. - bitget.com
Kiora Pharmaceuticals Announces $5 Million Private Placement Financing - TipRanks
Kiora Pharmaceuticals IncEnters Securities Purchase Agreement On April 3, 2026SEC Filing - TradingView
Why Did KPRX Stock Surge 17% Pre-Market Today? - Stocktwits
Kiora Pharmaceuticals Raises $5 Million in Private Placement With $19 Million Warrant Upside - TradingView
Kiora (NASDAQ: KPRX) secures up to $24M in milestone-based private placement - Stock Titan
Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors - TMX Newsfile
Kiora Pharmaceuticals Surges 23.5% Intraday – What's Fueling the Rally? - bitget.com
Critical Outcome Technologies (OTCMKTS:COTQF) and Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Survey - Defense World
Kiora Pharmaceuticals Announces Chief Development Officer Resignation - TipRanks
Kiora Pharmaceuticals chief development officer to depart - Investing.com
Eric J. Daniels to Resign as Kiora Chief Development Officer Effective April 17, 2026 - TradingView
Kiora Pharmaceuticals (KPRX) CFO uses 929 shares to cover taxes - Stock Titan
Kiora (NASDAQ: KPRX) executive uses 929 shares to satisfy tax withholding - Stock Titan
Kiora (KPRX) CEO withholds 1,906 shares to cover stock taxes - Stock Titan
Kiora Pharmaceuticals (NASDAQ: KPRX) details CDO exit and trial progress - Stock Titan
Kiora says retinal disease trials keep enrolling after exec exit - Stock Titan
KPRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Will Kiora Pharmaceuticals Inc outperform its industry peersProduct Launch & Safe Entry Zone Identification - baoquankhu1.vn
Should I hold or sell Kiora Pharmaceuticals Inc nowQuarterly Market Review & Accurate Trade Setup Notifications - baoquankhu1.vn
Kiora Pharmaceuticals Inc reports results for the quarter ended September 30Earnings Summary - TradingView
Kiora Pharmaceuticals reports $10.8M loss for 2025 By Investing.com - Investing.com Canada
Kiora Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Results; Company Advances Retinal Disease Pipeline with Two Active Phase 2 Clinical Trials - Bitget
Kiora Pharmaceuticals reports $10.8M loss for 2025 - Investing.com
Kiora Pharmaceuticals posts 2025 net loss as expenses rise - TradingView
Kiora Pharmaceuticals 10-K: $0M Revenue, $(10.84)M Net Loss - TradingView
Kiora (NASDAQ: KPRX) posts 2025 loss while funding two active Phase 2 trials - Stock Titan
Retinal disease pipeline at Kiora Pharmaceuticals (NASDAQ: KPRX) - Stock Titan
If You Invested $1,000 in KIORA PHARMACEUTICALS INC (KPRX) - Stock Titan
Sectors Review: Is Kiora Pharmaceuticals Inc still a buy after recent gains2026 Trends & AI Driven Stock Reports - baoquankhu1.vn
KPRX Should I Buy - Intellectia AI
Kiora Pharmaceuticals Inc expected to post a loss of 67 cents a shareEarnings Preview - TradingView
Kiora Pharmaceuticals (NASDAQ: KPRX) CFO granted new stock and option awards - Stock Titan
Kiora Pharmaceuticals (KPRX) Upgraded to Strong Buy: Here's What You Should Know - MSN
Kiora Pharmaceuticals (KPRX) CDO uses 238 shares to cover tax withholding - Stock Titan
Kiora Pharmaceuticals (KPRX) CEO disposes 238 shares for taxes - Stock Titan
KPRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Market Fear: Can Kiora Pharmaceuticals Inc keep up with sector leadersRisk Management & Technical Pattern Based Signals - baoquankhu1.vn
KPRXKIORA PHARMACEUTICALS INC Latest Stock News & Market Updates - Stock Titan
Retail Trends: Is Kiora Pharmaceuticals Inc a defensive stockWeekly Trend Recap & Long-Term Growth Stock Strategies - baoquankhu1.vn
What is Kiora Pharmaceuticals Inc. s debt to equity ratioIPO Watch & Community Verified Swing Trade Signals - mfd.ru
SEC EDGAR Submission 0001104659-22-079906 - SEC.gov
Kiora Pharmaceuticals to Present at Oppenheimer's 36th Annual Healthcare Life Sciences Conference - TMX Newsfile
KPRX Technical Analysis & Stock Price Forecast - Intellectia AI
KPRX PE Ratio & Valuation, Is KPRX Overvalued - Intellectia AI
Can Kiora Pharmaceuticals Inc. stock hit record highs againMarket Sentiment Summary & Entry Point Confirmation Alerts - mfd.ru
Finanzdaten der Kiora Pharmaceuticals Inc-Aktie (KPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.47%
2.75%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):